An expert summarizes that the BCG-naive treatment space is gaining renewed attention due to global BCG shortages and variable patient responses, highlighting the urgent need for alternative therapies and personalized strategies that can better serve patients who may not benefit optimally from standard BCG treatment.
From a practical standpoint, integrating ctDNA into clinical practice poses challenges.
An expert summarizes that the emerging concept of broad immune potentiation—exemplified by therapies like Terra-002—seeks to activate multiple immune pathways for a more durable antitumor response in bladder cancer, offering a promising shift from traditional, narrowly targeted treatments and paving the way for more personalized and effective care.
Jansen stresses that testosterone is not a cure-all and often requires adjunct evaluation and management of other conditions such as sleep apnea or thyroid disorders.
Ashley G. Winter, MD, reflects on the need for FDA approved testosterone formulations in women, emphasizing that urologists are well-positioned to drive change in this space.
Vikram M. Narayan, MD, FACS, offers advice for institutions that are considering investments in technology to improve clinical workflows.
A key diagnostic clue is that individuals with disordered eating often have unusually precise awareness of their food and fluid intake.
Panelists discuss how patient adherence to oral androgen deprivation therapy has been reliable in both clinical trials and practice, with the convenience of daily pills and portability during travel contributing to good compliance rates.
Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular risk profile, and the potential for rapid testosterone recovery.
Sonam Saxena discusses recent findings on trends in surgery vs active surveillance for localized kidney cancer.
“Right now, it is our counseling against the warning label,” Winter emphasized.
Katherine Chan, MD, MPH, details the design of the pivotal phase 1/2 LEGEND trial, assessing the safety and efficacy of detalimogene voraplasmid in NMIBC.
Findlay notes that urinary diversion has increased over time, potentially due to functional decline and growing burdens on patients and caregivers.
Beyond clinical metrics, Pezzella praised the device’s user-friendly, sophisticated design.
"We are not offering patients comprehensive management unless we consider hormone therapies," says Ashley G. Winter, MD.
An expert summarizes that TARA-002, a novel immunotherapy derived from Streptococcus pyogenes, is showing promising results in a phase 2 trial for non–muscle-invasive bladder cancer—particularly in BCG-unresponsive patients—and may offer a much-needed alternative amid current treatment limitations and BCG shortages.
An expert summarizes that bladder cancer management is evolving from traditional radical surgery toward more personalized, less invasive approaches—highlighting promising therapies like TARA-002 that activate broad immune responses, address both BCG-unresponsive and BCG-naive patients amid shortages, and offer familiar, manageable administration—while underscoring the critical need to carefully interpret diverse clinical trial data, optimize treatment sequencing and combinations, and integrate advanced diagnostics to improve outcomes, preserve bladder function, and reduce overtreatment in this complex disease landscape.
According to Song, novel aspiration technologies are reshaping not only care delivery, but also long-term treatment outcomes.
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, discusses the strong connection between eating disorders and urinary incontinence in women.
Panelists discuss how oral androgen deprivation therapy options like relugolix fit into current treatment strategies across multiple patient categories, offering advantages in rapid onset, quick recovery, and convenience, particularly for patients requiring short-term treatment or those with cardiovascular risk factors.
Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more rapid onset, faster recovery, and avoidance of testosterone flare.
Ultimately, the take-home message for practicing urologists is to apply TMT judiciously, taking into account the patient's clinical profile, personal values, and financial situation.
One crucial recommendation is incorporating an ergonomic training module into the curriculum.
Betty Wang, MD, said she envisions ctDNA integrating into existing surveillance protocols for patients with high-risk NMIBC.
One consideration is the setting in which the procedure is performed.
A panelist discusses how patients with high-risk localized prostate cancer receiving treatment intensification should complete an 18- to 24-month course of systemic therapy with radiation for optimal cure rates, rather than stopping early due to prostate-specific antigen (PSA) response alone.
The research identified several risk factors for high burnout, including younger age, female gender, and longer working hours.
Andrea Pezzella, MD, URPS, FACOG, stressed the need for offering patients comprehensive information on all available therapies.
Howard B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.
Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and optimized therapy sequencing to improve outcomes, as current approaches still leave many patients at risk of relapse despite expanding therapeutic options.
